Menu
X

Treatment Details

Molnupiravir

Brand Name: Lagevrio
Drug Class: Nuceloside analog
FDA Category: Prescription Medication
Ratings
0 Comments
Views

n/a

Effectiveness

n/a

Side Effects

n/a

Cost

Relevant Studies

Bmj 2022 074572 – www.bmj.com

Read Study →

Molnupiravir – www.covid19treatmentguidelines.nih.gov

Read Study →

PMC10029330 – www.ncbi.nlm.nih.gov

Read Study →

How it works:

Inhibits viral replication by promoting mutations in the RNA of viruses

Dosage Form: Tablet Capsule - 200mg

Common Usage: COVID-19 infection

Precautions:

Pregnancy

There are no available human data on the use of LAGEVRIO in pregnant individuals to evaluate the risk of major birth defects, miscarriage or adverse maternal or fetal outcomes; therefore, LAGEVRIO is not recommended during pregnancy

Lactation

Based on the potential for adverse reactions in the infant from LAGEVRIO, breastfeeding is not recommended during treatment with LAGEVRIO and for 4 days after the final dose

Warnings

Warnings: Hypersensitivity, not recommended for those less than 18 due to bone and cartilage toxicity

© 2024 CompendiRx.com. All Rights Reserved. Information on Ratings and Reviews is reported by our members and is not medical advice.

Related Medicines

Write a Review

Subscribe
Notify of
guest
What symptom did you target?
Effectiveness rating
Side effect rating
Cost
0 Comments
Inline Feedbacks
View all comments

© 2024 CompendiRx.com. All Rights Reserved. Information on Ratings and Reviews is reported by our members and is not medical advice.

Submission Date: Apr 16, 2024, 08:01AM

Last Update Date: Sep 14, 2024, 06:50PM